Alice Fabarius
Overview
Explore the profile of Alice Fabarius including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
2233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naumann N, Rudelius M, Lubke J, Christen D, Bresser J, Sotlar K, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339343
Within our nationwide registry, we identified a D816V mutation ( D816V in 280/299 (94%) patients with advanced systemic mastocytosis (AdvSM). Age, cytopenias and the presence of additional somatic mutations confer...
2.
Lubke J, Naumann N, Hoffmann O, Horny H, Sotlar K, Rudelius M, et al.
Sci Rep
. 2024 Jan;
14(1):702.
PMID: 38184670
In 70 patients with KIT D816V positive systemic mastocytosis (SM) including 36 patients with advanced SM (AdvSM), we correlated the extent of reported mucosal mast cell ([m]MC) infiltration of the...
3.
Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, et al.
Leukemia
. 2023 Dec;
38(2):318-325.
PMID: 38129513
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic markers that reflect...
4.
Cross N, Ernst T, Branford S, Cayuela J, Deininger M, Fabarius A, et al.
Leukemia
. 2023 Oct;
37(11):2150-2167.
PMID: 37794101
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of...
5.
Isfort S, Manz K, Teichmann L, Crysandt M, Burchert A, Hochhaus A, et al.
Ann Hematol
. 2023 Aug;
102(10):2741-2752.
PMID: 37592092
The approved dose of bosutinib in chronic phase CML is 400 mg QD in first-line and 500 mg QD in later-line treatment. However, given that gastrointestinal (GI) toxicity typically occurs...
6.
Spiess B, Kleiner H, Tarnopolscaia I, Naumann N, Fabarius A, Hofmann W, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568730
Reverse transcriptases (RT) are essential tools in fusion transcript monitoring in chronic myeloid leukemia (CML). The RT type and cDNA priming method may impair the stoichiometry of cDNA synthesis, thereby...
7.
Metzgeroth G, Steiner L, Naumann N, Lubke J, Kreil S, Fabarius A, et al.
Leukemia
. 2023 Jul;
37(9):1860-1867.
PMID: 37454239
In a registry-based analysis of 135 patients with "myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions" (MLN-TK; FIP1L1::PDGFRA, n = 78; PDGFRB, diverse fusions, n = 26; FGFR1, diverse,...
8.
Christiani E, Naumann N, Weiss C, Spiess B, Kleiner H, Fabarius A, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174118
The achievement of major molecular response (MMR, ≤ 0.1% IS) within the first year of treatment with tyrosine kinase inhibitors (TKI) is a milestone in the therapeutic management of patients...
9.
Lubke J, Naumann N, Metzgeroth G, Kreil S, Brand T, Horny H, et al.
Ann Hematol
. 2023 Apr;
102(8):2077-2085.
PMID: 37012462
We sought to evaluate the efficacy of the purine analogue cladribine in 79 patients with advanced systemic mastocytosis (AdvSM) using data from the 'German Registry on Disorders of Eosinophils and...
10.
Xu Q, Streuer A, Jann J, Altrock E, Schmitt N, Flach J, et al.
Nat Commun
. 2023 Mar;
14(1):1497.
PMID: 36932114
Limited response rates and frequent relapses during standard of care with hypomethylating agents in myelodysplastic neoplasms (MN) require urgent improvement of this treatment indication. Here, by combining 5-azacytidine (5-AZA) with...